Bionomics’ BNC210 anti-anxiety drug enters phase I
Friday, 21 December, 2012
Bionomics’ (ASX:BNO) US partner, Ironwood Pharmaceuticals, has moved forward with development of anti-anxiety drug IW-2143, also known as BNC210, by initiating a phase I trial.
The company filed an Investigational New Drug application with the Food and Drug Administration in November.
The phase I trial will assess safety and pharmacokinetics of BNC210 in healthy volunteers using single and multiple doses.
“This is the first US clinical trial of IW-2143 and this news is welcomed by Bionomics as a strong signal of the progress being made by Ironwood in moving ahead with the study of IW-2143,” said Bionomics CEO and MD, Dr Deborah Rathjen.
Bionomics is expecting a US$2m milestone payment from Ironwood as the trial progresses.
Bionomics’ (ASX:BNO) lost half a cent in morning trading, sitting at 35c as of around 11am Friday.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
